Friedl-Naderer Johanna
SEC CIK 1915598 · EDGAR
BoughtSold
Most active insiders at DYN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Rhodes Jason P | Dir | — | $129.10M |
| 2 | Kersten Dirk | Dir | — | $38.57M |
| 3 | Cox John | CEO, Pres, Dir | — | $443.7K |
| 4 | Posner Brian S | Dir | $274.8K | — |
| 5 | Kerr Douglas | Chief Medical Off | — | $233.1K |
| 6 | Lucera Erick | CFO | — | $228.7K |
| 7 | Friedl-Naderer Johanna | Chief Commercial Off | — | $43.4K |
| 8 | Lubner David Charles | Dir | — | — |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-08 16:15 | 2026-09-04+ | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | S - Sale | $23.42 | -1,085 | 152.9K | -0.7% | -$25.4K |
| T | 2026-08-17 16:08 | 2026-08-13 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | S - Sale | $26.28 | -226 | 154.0K | -0.1% | -$5,939 |
| T | 2026-06-17 16:07 | 2026-06-16 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | S - Sale | $18.33 | -145 | 154.2K | -0.1% | -$2,658 |
| T | 2026-05-14 16:05 | 2026-05-13 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | S - Sale | $18.36 | -228 | 154.4K | -0.1% | -$4,186 |
| T | 2026-03-06 | 2026-03-05 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | S - Sale | $14.90 | -148 | 154.6K | -0.1% | -$2,205 |
| D | 2026-02-17 | 2026-02-12 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | A - Grant | $0.00 | +60.0K | 154.7K | +63% | $0 |
| T | 2025-12-05 | 2025-12-05 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | S - Sale | $20.72 | -144 | 94.7K | -0.2% | -$2,984 |
| MT | 2025-09-08 | 2025-09-04+ | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | S - Sale | $13.29 | -1,038 | 94.9K | -1% | -$13.8K |
| T | 2025-06-06 | 2025-06-05 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | S - Sale | $13.35 | -146 | 95.9K | -0.2% | -$1,949 |
| T | 2025-03-13 | 2025-03-13 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | S - Sale | $12.12 | -143 | 96.1K | -0.1% | -$1,733 |
| D | 2024-12-06 | 2024-12-04 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | A - Grant | $0.00 | +37.8K | 96.2K | +65% | $0 |
| D | 2024-09-03 | 2024-09-03 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Off | A - Grant | $0.00 | +58.4K | 58.4K | New | $0 |
| 2023-03-07 | 2023-03-03 | VIR | Vir Biotechnology, Inc. | Friedl-Naderer Johanna | EVP, COO | S - Sale | $22.82 | -1,482 | 148.5K | -1.0% | -$33.8K | |
| D | 2023-02-24 | 2023-02-22 | VIR | Vir Biotechnology, Inc. | Friedl-Naderer Johanna | EVP, COO | A - Grant | $0.00 | +60.0K | 150.0K | +67% | $0 |
| D | 2022-03-08 | 2022-03-02 | VIR | Vir Biotechnology, Inc. | Friedl-Naderer Johanna | Chief Business Off, Gbl | A - Grant | $0.00 | +90.0K | 90.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations